A Pharmacokinetic Study of DW6012 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

Healthy Subjects Clinical Trial

Official title:

A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination of DW6012 and Loose-combination of Each Component in Healthy Adult Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05403281
• Other study ID #: DW6012-I-1
• Status: Completed
• Phase: Phase 1
• Start date: November 5, 2021
• Est. completion date: March 28, 2022

Study information

• Verified date: May 2022
• Source: Dong Wha Pharmaceutical Co. Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6012 and each component in healthy adult volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 41
• Est. completion date: March 28, 2022
• Est. primary completion date: December 3, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Healthy subjects aged up to 19 years

• Subjects weighing at least 50.0 kg and no more than 100 kg (inclusive) with a BMI between 18.5 kg/m2 and 30.0 kg/m2

• Subjects with neither congenital nor chronic diseases requiring treatment, and no abnormal symptoms or findings upon medical examination

• Subjects considered eligible for the study participation in accordance to the results of clinical laboratory tests, vital signs, physical examinations and 12-lead ECG conducted at the time of screening, based on the investigational product (IP) characteristics

• Subjects who has a full understanding in participation of the study, voluntarily provide a written consent in participation, and give full agreement in following the subject guidelines throughout the entire study period

Exclusion Criteria:

• Subjects with any clinically significant hepatic, renal, nervous, respiratory, endocrine, circulatory, tumor, genitourinary, cardiovascular, digestive, musculoskeletal systemic diseases or other medical history

• Subjects with genetic problems such as Lapp lactase deficiency (Lapp) or galactose intolerant galactose due to galactose intolerance

• Subjects with a past medical history of gastrointestinal disease or gastrointestinal surgeries which may affect the absorption, distribution, metabolism and excretion of the IP

• Pregnant subjects with a positive urine HCG test, or lactating female subjects

• Subjects with hypersensitivity reactions or a clinically significant medical history of hypersensitivity reactions to drug substances and additives containing drug substances or other drugs

• Subjects with clinically significant 12-lead ECG findings at the time of screening

• Subjects with clinically significant laboratory test results as follows: Liver function test (AST, ALT, ALP, ?-GTP and total bilirubin), Creatinine, eGFR

• Subjects with a past history of drug abuse or a positive urine drug test

• Subjects with SBP = 150 mmHg or = 90 mmHg; DBP = 100 mmHg or = 60 mmHg; PR = 40 bpm or = 100 bpm at the time of screening

• Subjects following an unusual diet or consumption of food which may affect the absorption, distribution, metabolism and excretion of the IP

• Subjects who have administered any prescription drugs or herbal medicines that may affect the characteristics of clinical investigational drugs within 2 weeks prior to the first administration date, or have administered any over-the-counter (OTC) or vitamin preparations within 10 days

• Subjects taking drugs known to significantly induce or inhibit drug metabolizing enzymes, including barbitals within 1 months prior to the first IP administration

• Subjects who have participated and were given any other study drugs in other clinical study within 6 months prior to the first IP administration

• Subjects who have consistently drunk alcohol within 6 months

• Subjects who have smoked more than 10 cigarettes/day on average

• Subjects who have eaten or cannot refrain from eating grapefruit (grapefruit)-containing food from 48 hours before the first administration until the time of PSV

• Subjects who have consumed or cannot refrain from consuming caffeine-containing food during the period from 24 hours prior to administration of each period to the time of the last blood sampling

• Subjects who have done and are unable to refrain from strenuous activity

• Subjects who are planning for pregnancy or not willing to use a medically reliable forms of contraception

• Subjects otherwise considered ineligible for participation due to other reasons including clinical laboratory test results not mentioned in the inclusion/exclusion criteria at the investigator's discretion

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• DW6012
Drug: DW6012 Single oral administration of DW6012 after an overnight fast Drug: Dapagliflozin and Sitagliptin Single oral administration of Dapagliflozin and Sitagliptin after an overnight fast

Locations

Country	Name	City	State
Korea, Republic of	Chungbuk National University Hospital	Cheongju-si

Sponsors (1)

Lead Sponsor	Collaborator
Dong Wha Pharmaceutical Co. Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AUC0-t of Dapagliflozin and Sitagliptin		up to 48 hours
Primary	Cmax of Dapagliflozin and Sitagliptin		up to 48 hours
Secondary	AUCinf		up to 48 hours
Secondary	Tmax		up to 48 hours
Secondary	t1/2		up to 48 hours
Secondary	CL/F		up to 48 hours
Secondary	Vd/F		up to 48 hours
Secondary	AUCextra		up to 48 hours